Publications by authors named "Marc Andrea"

Claim this Profile
P
Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV).
Tanja Holzhey, Wolfram Pönisch, Song-Yau Wang, Madlen Holzvogt, Bruno Holzvogt, Marc Andrea, Andreas Schwarzer

J Cancer Res Clin Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077).
Juliane Beck, Andreas Schwarzer, Dietrich Gläser, Lars-Olof Mügge, Jens Uhlig, Marc Andrea

J Cancer Res Clin Oncol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV).
Hannah Tessenow, Madlen Holzvogt, Bruno Holzvogt, Marc Andrea, Simone Heyn

J Cancer Res Clin Oncol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma.
Wolfram Poenisch, Madlen Plötze, Bruno Holzvogt, Marc Andrea, Thomas Schliwa, Andreas Schwarzer

J Cancer Res Clin Oncol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma.
Wolfram Pönisch, Bruno Holzvogt, Madlen Plötze, Marc Andrea, Malvina Bourgeois, Andreas Schwarzer

J Cancer Res Clin Oncol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure.
Wolfram Pönisch, Barbara Moll, Malvina Bourgeois, Marc Andrea, Thomas Schliwa, Andreas Schwarzer

J Cancer Res Clin Oncol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone.
Wolfram Pönisch, Marc Andrea, Ina Wagner, Doreen Hammerschmidt, Ute Kreibich, Andreas Schwarzer

J Cancer Res Clin Oncol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis